Differential effectiveness of antipsychotics in borderline personality disorder: Meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains

Journal of Clinical Psychopharmacology

Volumn 31, Issue 4, 2011, Pages 489-496

  Ingenhoven, Theo J M ^a   Duivenvoorden, Hugo J ^b  

^a Pro Persona   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

antipsychotics; borderline personality disorder; drug therapy; meta analysis; RCT

Indexed keywords

ARIPIPRAZOLE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE;

ALGORITHM; ANGER; ANXIETY DISORDER; BORDERLINE STATE; DRUG EFFICACY; HUMAN; IMPULSIVENESS; MENTAL INSTABILITY; META ANALYSIS; MOOD DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79960582356     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182217a69     Document Type: Review

References (42)

1. Zanarini MC, Frankenburg FR, Hennen J, et al. The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. Am J Psychiatry. 2003;160:274-283. (Pubitemid 41110452)
2. Zanarini MC, Frankenburg FR, Khera GS, et al. Treatment histories of borderline inpatients. Compr Psychiatry. 2001;65:903-907.
3. American Psychiatric Association. Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry. 2001;158(suppl 10):1-52.
4. Oldham JM. Guideline Watch: Practice Guideline for the Treatment of Patients with Borderline Personality Disorder. Arlington, VA: American Psychiatric Association. Focus. 2005;3:396-400. (Available online at: http://focus.psychiatryonline.org/cgi/content/full/3/3/396).
5. Rinne T, Ingenhoven T. Pharmacotherapy of severe personality disorders: a critical review. In: van Luyn B, Akhtar S, Livesley WJ, eds. Severe Personality Disorders, Major Issues in Everyday Practice. New York, Cambridge, Melbourne: The Cambridge Press; 2007.
6. Herpertz SC, Zanarini M, Schulz CS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of personality disorders. World J Biol Psychiatr. 2007;8:212-244. (Pubitemid 350018476)
7. National Collaborating Centre for Mental Health. Borderline Personality Disorder. The NICE Guideline on Treatment and Management. National Clinical Practice Guideline No. 78. Leicester, UK: British Psychological Society & Royal College of Psychiatrists; 2009. (Available online at: http://www.nice.org. uk/nicemedia/live/12125/43045/43045.pdf).
8. Kendall T, Burbeck R, Bateman A. Pharmacotherapy for borderline personality disorder: NICE guideline. Br J Psychiatry. 2010;196:158-159.
9. CBO. Centraal Begeleidings Orgaan, Landelijke Stuurgroep Multidisciplinaire Richtlijnontwikkeling in de GGZ. Multidisciplinaire Richtlijn voor de diagnostiek en behandeling van volwassen patiënten met een persoonlijkheidsstoornis. [Multi Disciplinary Guideline for the Diagnosis and Treatment of Adult Patients with Personality Disorders], Utrecht, Trimbos-Instituut, 2008.
10. Soloff P. Symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation. Bull Menninger Clin. 1998;62:195-214.
11. Soloff P. Psychopharmacology of borderline personality disorder. Psychiatr Clin North Am. 2000;23:169-192, ix. (Pubitemid 30140478)
12. Ingenhoven T, Lafay P, Rinne T, et al. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry. 2010;71:14-25.
13. Altman D, Bland J. Detecting skewness from summary information. BMJ. 1996;313:1200. (Pubitemid 26381905)
14. Cohen J. Statistical Power Analysis for Behavioural Science. 2nd ed. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988.
15. Hedges L, Olkin I. Statistical Methods for Meta-Analysis. London, UK: Harcourt Brace Javanovich; 1985.
16. Egger M, Davey-Smith G, Altman D. Systematic Reviews in Healthcare. London, UK: British Medical Journal Books; 2001.
17. Higgins J, Thompson S, Beeks J, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560. (Pubitemid 37088507)
18. Montgomery S, Montgomery D. Pharmacological prevention of suicidal behaviour. J Affect Disord. 1982;4:291-298. (Pubitemid 13196492)
19. Goldberg S, Schulz S, Schulz P, et al. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry. 1986;43:680-686. (Pubitemid 16094180)
20. Cowdry R, Gardner D. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988;45:111-119. (Pubitemid 18052841)
21. Soloff PH, George A, Natham RS, et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol. 1989;9:238-246. (Pubitemid 19198957)
22. Soloff PH, Cornelius J, George A, et al. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry. 1993;50:377-385. (Pubitemid 23143127)
23. Cornelius J, Soloff P, Perel J, et al. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry. 1993;150:1843-1848. (Pubitemid 23356578)
24. Zanarini M, Frankenburg F. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001;62:849-854. (Pubitemid 33131170)
25. Bogenschutz M, Nurnberg H. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:104-109.
26. Soler J, Pascual J, Campins M, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005;162:1221-1224. (Pubitemid 40770712)
27. Zanarini MC, Schulz SC, Detke HC, et al. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized double-blind placebo-controlled study (P102). Presented at the XXIVth CINP Congress, Chicago, IL, July 9-13. Int J Neuropsychopharm. 2006;9(suppl 1):S191.
28. Nickel M, Meuhlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006;163:833-838. (Pubitemid 44464531)
29. Pascual JC, Soler J, Puigdemont D, et al. Ziprazidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry. 2008;69(4):603-608. (Pubitemid 351792335)
30. Schulz SC, Zanarini M, Detke H, et al. Olanzapine for the treatment of borderline personality disorder: a flexible-dose12-week randomized double-blind placebo-controlled study (P101). Presented at the XXIVth CINP Congress, Chicago, IL, July 9-13. Int J Neuropsychopharm. 2006;9(suppl 1):S191.
31. Schulz SC, Zanarini MC, Bateman A, et al. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomized double-blind placebo-controlled study. Br J Psychiatry. 2008;193:485-492.
32. Linehan MM, McDavid JD, Brown MZ, et al. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008;69:999-1005. (Pubitemid 351944956)
33. van den Broek PJA, Penterman BJM, Hummelen KW, et al. The effect of quetiapine on psychotic-like symptoms and general psychopathology in patients with borderline personality disorder: a randomized placebo-controlled trial. Eur Neuropsychopharmacol. 2008;18(suppl 4):S425-S426.
34. Eli Lilly. Efficacy and Safety of Olanzapine in Patients with Borderline Personality Disorder: A Randomized, Double-Blind Comparison with Placebo. (2006). (Summary ID 6253, Clinical Study Summary, 20 March 2007: Study F1D-MC-HGKK. (Available at: http://www.clinicalstudyresults.org/documents/ company-study-2339-0.pdf ).
35. Eli Lilly. Efficacy and Safety of Olanzapine in Patients with Borderline Personality Disorder: A Randomized, Flexible Dose, Double-Blind Comparison with Placebo. (2007). (Summary ID 6257, Clinical Study Summary, 13 August 2007: Study F1D-MC-HGKK. Available at: http://www.clinicalstudyresults.org/documents/ company-study-3631-0.pdf. Ly170053. F1D-MC-HGKK, protocol phase 3).
36. Koenigsberg H, Reynolds D, Goodman M, et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry. 2003;64:628-634. (Pubitemid 36750138)
37. American Psychiatric Association. Proposed Changes in Personality Disorders for DSM-5. January 11, 2010. (Available at: http://www.dsm5.org/ ProposedRevision/pages/PersonalityandPersonalityDisorders.aspx).
38. Binks C, Fenton M, McCarthy L, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2006;3:CD005653.
39. Nose M, Cipriani A, Biancosino B, et al. Efficacy of pharmacotherapy against traits of borderline personality disorder: meta-analysis of randomized controlled trails. Int Clin Psychopharmacol. 2006;21:345-353. (Pubitemid 44498276)
40. Mercer D, Douglass AB, Links PS. Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms. J Personal Disord. 2009;23(2):156-174.
41. Lieb K, Volm B, Ruker G, et al. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry. 2010;196:4-12.
42. Shafti SS, Shahveisi B. Olanzapine versus haloperidol in the management of borderline personality disorder. A randomized double-blind trial. J Clin Psychopharmacol. 2010;30(1):44-47.